Rezolute, Inc.

The Rezolute team had a great time at the 15th Annual German Family Conference hosted by Kongenitaler Hyperinsulinismus, eV last week in Berlin! We are grateful to the organizers for giving us the opportunity to meet with families, hear their stories, and share our novel approach to a potential treatment for #cHI.  #sunRIZE #hyperinsulinism #hypoglycemia #raredisease

As #HypoglycemiaAwarenessWeek comes to a close, Rezolute would like to shine a spotlight on the outstanding work our partner patient advocacies do each and every day to support patients and families living with #CongenitalHyperinsulinism. congenitalhi.org hyperinsulinism.co.uk https://lnkd.in/e3Ev92za hyperinsulinismus.de #hypoglycemia #clinicaltrials #raredisease

Compassionate use programs play a crucial, yet often underappreciated, role in drug development; providing patients, particularly those with rare diseases, access to potentially life-saving therapies that may positively impact the trajectory of their health outcomes.   We're thrilled to publish, in partnership with WEP Clinical and Ana Paula Tediosi, this two-part series on compassionate use programs and the meaningful benefits in the development of a potential treatment for multiple forms of insulin receptor mediated hypoglycemia. https://bit.ly/4eXiL0O #clinicaltrials #clinicalresearch #raredisease #hypoglycemiaawarenessweek

Interested in cutting edge science for treating rare disease at a company with two late-stage programs? Check out this role and other opportunities to join our growing team! https://lnkd.in/ecAZetUr

Today we reported our Q4 and full year fiscal 2024 financial results. Learn more about recent progress and plans to advance our antibody therapy, RZ358 (ersodetug), in two Phase 3 trials for the treatment of hypoglycemia resulting from congenital and acquired forms of hyperinsulinism: https://bit.ly/4e7BQ0w

Tomorrow, Dr. Arshad M. Khanani will be presenting "Results from the Phase 2a study of a novel, orally administered Plasma Kallikrein Inhibitor in patients with Diabetic Macular Edema (DME)" at the European Society of Retina Specialists (EURETINA). Learn more about our novel PKIs and unique approach to DME.

On 9/15 Dr. Quan Dong Nguyen will be presenting "Safety and Efficacy of RZ402, a Novel, Orally Administered Plasma Kallikrein Inhibitor, from a Phase 2a Study in Patients with Diabetic Macular Edema” at The Retina Society Annual Meeting. Swing by and say hello!

We are thrilled the FDA has lifted the partial clinical holds on RZ358 for the treatment of congenital hyperinsulinism, allowing for U.S. inclusion in the ongoing global Phase 3 sunRIZE study: https://bit.ly/4cSDz8o

The Rezolute team is traveling to the 2024 Bradykinin Symposium in Berlin where Ian Yates will be presenting a poster titled, “Discovery of Highly Potent Plasma Kallikrein Inhibitors”, and Jeffrey Breit, Ph.D. will give a talk titled, “Novel Rezolute Plasma Kallikrein Inhibitors Prevent Edema in Animal Models”. Say hi to the team and learn more about our novel PKIs! https://lnkd.in/dBRdwED7

Rezolute management will be participating in the upcoming H.C. Wainwright & Co., LLC and Cantor Fitzgerald conferences. We hope to see you there! https://bit.ly/3TaEuKh